Stoke Therapeutics Faces Mounting Losses as Earnings Loom

Stoke Therapeutics Inc reports earnings today with analysts bracing for a significant loss of $0.80 per share. The biotech faces a critical test as losses have deepened over recent quarters and full-year 2026 estimates point to a dramatic deterioration. With the stock trading below most short-term moving averages but maintaining strong analyst support, investors will scrutinize whether the company can stabilize its financial trajectory.

Part 1: Earnings Preview

Stoke Therapeutics Inc is a biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases by upregulating protein expression. The company's lead programs target conditions caused by haploinsufficiency, where one functional copy of a gene is insufficient to maintain normal function.

STOK reports earnings today with analysts expecting a loss of $0.80 per share on consensus estimates from 4 analysts. The most recently reported quarter (December 2025) showed a loss of $0.97 per share, marking a significant deterioration from prior periods. Compared to the same quarter last year (March 2025), when the company reported earnings of $1.90 per share, the year-over-year comparison reveals a dramatic swing of -$2.70 per share or -142.11%.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will focus on updates regarding the company's lead programs and any clinical trial milestones that could validate the therapeutic approach and justify the current cash burn rate.

Cash Runway and Burn Rate: With mounting quarterly losses, the company's financial position and ability to fund operations through key clinical catalysts will be scrutinized closely by investors assessing dilution risk.

Regulatory Pathway Clarity: Any guidance on regulatory interactions or timelines for potential approvals could significantly impact investor confidence in the company's ability to reach commercialization and generate revenue.

Analyst commentary ahead of the release reflects cautious optimism tempered by near-term financial realities, with most maintaining buy ratings based on long-term pipeline potential while acknowledging the challenging path to profitability.

Part 2: Historical Earnings Performance

Stoke Therapeutics has demonstrated highly volatile earnings performance over the past four quarters, with results swinging dramatically between beats and misses.

The pattern began with an extraordinary +613.51% beat in March 2025, when the company reported $1.90 per share against expectations of a $0.37 loss. This exceptional result was followed by a +29.82% beat in June 2025 (loss of $0.40 vs. estimated loss of $0.57). However, the trend reversed sharply in the second half of 2025, with a -20.37% miss in September (loss of $0.65 vs. estimated loss of $0.54) and a -29.33% miss in December (loss of $0.97 vs. estimated loss of $0.75).

The recent trajectory shows deteriorating performance relative to expectations, with losses deepening and the company missing estimates by increasingly wider margins in the two most recent quarters. This shift from significant beats to meaningful misses suggests either changing business fundamentals or a recalibration of analyst expectations that hasn't kept pace with operational realities.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

The stock's price behavior around earnings will depend on the reporting time, which has not been specified for today's release.

Historical price action shows significant volatility following earnings releases, with an average absolute move of 2.90% on Day 0 and 13.26% on Day +1. The Day +1 moves have been particularly dramatic, ranging from a -9.94% decline in November 2025 to a stunning +24.98% surge in August 2025. The most extreme reaction occurred in March 2024, when the stock soared +58.31% on Day +1. The wide average Day 0 range of 8.37% and Day +1 range of 15.09% indicate substantial intraday volatility regardless of direction, suggesting investors should prepare for significant price swings in either direction following the release.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 21.47% (±$6.91), which is substantially higher than the historical average Day 0 move of 2.90% but more aligned with the average Day +1 move of 13.26%. This elevated implied volatility suggests options traders are anticipating a more dramatic reaction than typical, potentially reflecting heightened uncertainty around the company's financial trajectory and pipeline developments.

Part 3: What Analysts Are Saying

Analyst sentiment remains strongly bullish despite the company's recent earnings misses and mounting losses. The consensus includes 11 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with no sell recommendations among the 13 analysts covering the stock. This translates to an average recommendation of 4.77 out of 5.0, representing very strong conviction.

The average price target of $45.07 implies 40% upside from the current price of $32.18, with estimates ranging from a low of $35.00 to a high of $60.00. The wide target range reflects differing views on the timeline and probability of clinical and commercial success.

Recent sentiment has shown modest strengthening, with the number of Strong Buy ratings increasing from 10 to 11 over the past month while other rating categories remained stable. The average recommendation improved slightly from 4.75 to 4.77, indicating analysts are maintaining or even increasing their conviction despite the challenging near-term financial picture. This suggests the analyst community is looking through current losses and focusing on longer-term pipeline value and commercial potential.

Part 4: Technical Picture

The Barchart Technical Opinion shows a Buy signal at 64%, though momentum has weakened from 80% Buy last week and 88% Buy last month, indicating deteriorating technical strength heading into the earnings release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled considerably from recent highs
• Medium-term (50% Buy): Neutral-to-positive reading indicates consolidation in the intermediate timeframe with no clear directional bias
• Long-term (100% Buy): Strong buy signal reflects confidence in the longer-term uptrend despite recent weakness

Trend Characteristics: The signal strength is rated as Average with direction characterized as Weakest, suggesting the technical environment is losing momentum at a critical juncture just as earnings arrive.

The stock is trading at $32.18, positioned below the 5-day ($32.66), 10-day ($33.77), 20-day ($34.84), and 50-day ($32.71) moving averages, indicating short-term weakness. However, the price remains above the 100-day ($31.42) and 200-day ($25.21) moving averages, confirming the longer-term uptrend remains intact.

The technical setup presents a mixed picture heading into earnings. While the longer-term trend structure remains supportive with the stock well above its 200-day moving average, the recent breakdown below all short-term moving averages and weakening momentum signals suggest vulnerability. The deteriorating Barchart Opinion from 88% to 64% over the past month indicates technical pressure is building. Combined with the options market pricing in a 21% move, traders should be prepared for heightened volatility, with key support at the 100-day moving average of $31.42 and resistance at the 20-day moving average of $34.84.